| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G | HIRSCHMAN ORIN (Filed by) | ||
8-K | Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis | ||
SCHEDULE 13G/A | Bain Capital Life Sciences Opportunities III, LP (Filed by) | ||
10-Q | Form 10-Q | ||
8-K | Kyverna Therapeutics Reports Q2 2026 Financial Results and Pipeline Progress | ||
SCHEDULE 13G | BlackRock, Inc. (Filed by) | ||
8-K | Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel | ||
8-K | Kyverna Therapeutics Amends Loan and Security Agreement to Extend Term A Loan Availability | ||
8-K | Kyverna Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders | ||
4 | CLARK IAN T (Reporting) | ||
4 | Cohen Fred E (Reporting) | ||
4 | SEIDENBERG BETH C (Reporting) |
